AstraZeneca
AZN
546 hedge funds and large institutions have $17.4B invested in AstraZeneca in 2018 Q3 according to their latest regulatory filings, with 66 funds opening new positions, 150 increasing their positions, 197 reducing their positions, and 47 closing their positions.
207% more call options, than puts
Call options by funds: $225M | Put options by funds: $73.5M
114% more capital inflows, than outflows
Capital inflows: $2.17B | Capital outflows: $1.02B
40% more first-time investments, than exits
New positions opened: 66 | Existing positions closed: 47
3% more funds holding
Funds holding: 531 → 546 (+15)
0.98% more ownership
Funds ownership: 13.16% → 14.14% (+0.98%)
24% less repeat investments, than reductions
Existing positions increased: 150 | Existing positions reduced: 197
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$774M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$570M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$157M |
| 4 |
GQG Partners
Ft. Lauderdale,
Florida
|
+$102M |
| 5 |
Primecap Management
Pasadena,
California
|
+$89.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$123M |
| 2 |
Schafer Cullen Capital Management
New York
|
-$102M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$77.3M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$65.6M |
| 5 |
Dodge & Cox
San Francisco,
California
|
-$61.8M |
AZN Hedge Fund Activity: Q3 2018 in Review
546 of the 4,393 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q3 2018, worth a combined $17.4B — up 21% from $14.3B a quarter earlier.
Buyers outnumbered sellers: 66 funds opened new AZN positions and 47 closed out — a net gain of 19 holders — while 150 added to existing stakes and 197 trimmed.
The largest buyer was Jennison Associates, adding an estimated $774M. The largest seller was Bank of America, cutting an estimated $123M.
- 546 institutional investors held AstraZeneca (AZN) as of Q3 2018, up from 531 in Q2 2018.
- Funds reported $17.4B of AstraZeneca stock for Q3 2018, up 21% quarter-over-quarter.
- 66 funds opened new AstraZeneca positions in Q3 2018 and 47 closed out, a net change of +19 holders.
- The largest AstraZeneca buyer in Q3 2018 was Jennison Associates, an estimated $774M added.
- The largest AstraZeneca seller in Q3 2018 was Bank of America, an estimated $123M sold.
Based on aggregated 13F filings for Q3 2018.